Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]. (June 2021) - Garcia, Jacqueline S.; Swords, Ronan T.; Roboz, Gail J.; Jacoby, Meagan A.; Garcia-Manero, Guillermo; Hong, Wan-Jen; Yang, Xiaoqing; Zhou, Ying; Platzbecker, Uwe; Steensma, David P.; Wolff, Johannes E.; Fenaux, Pierre